Aptinyx Inc. – NASDAQ:APTX

Add to watchlist

$0.071

-0.02

-26.46%

Market closed

Open in about 6 hours

+51.18%

month

+42.43%

quarter

-64.44%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.13
EV/Sales	N/A
EV/EBITDA	0.45
Price/Sales	N/A
Price/Book	0.22
PEG ratio	N/A
EPS	-0.43

Revenue	N/A
EBITDA	-62.70M
Income	-29.16M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Aptinyx Inc. (NASDAQ:APTX): Profit margin
Jun 2022	0	-18.22M
Sep 2022	0	-15.09M
Dec 2022	0	25.96M
Mar 2023	0	-21.81M

Aptinyx Financials Estimate

Q Y

Aptinyx Inc. (NASDAQ:APTX): Analyst Estimates
2025	0	-3.38M

Analysts Price target
Financials & Ratios estimates

Aptinyx Inc. (NASDAQ:APTX): Earnings per share (EPS)
2023-05-11	-0.14	-0.29

Aptinyx Inc. (NASDAQ:APTX): Debt to assets
Jun 2022	92306000	30.20M	32.72%
Sep 2022	76205000	27.41M	35.97%
Dec 2022	66684000	28.39M	42.59%
Mar 2023	47963000	29.70M	61.94%

Aptinyx Inc. (NASDAQ:APTX): Cash Flow
Jun 2022	-14.75M	-133K
Sep 2022	-18.62M	-78K
Dec 2022	-10.37M	-2K
Mar 2023	-11.36M	-267K

Aptinyx alternative data

Aptinyx Inc. (NASDAQ:APTX): Employee count
Aug 2023	12
Sep 2023	12
Oct 2023	12
Nov 2023	12
Dec 2023	12
Jan 2024	12
Feb 2024	12
Mar 2024	12
Apr 2024	12
May 2024	12
Jun 2024	12
Jul 2024	12

Aptinyx
Hedge Funds Holdings Q1 2022

53.27% +2.19%

of APTX is owned by hedge funds

57 +10

hedge funds hold APTX stock

35.80M +1.22M

shares is hold by hedge funds

APTX hedge funds holdings changes

Aptinyx Inc. (NASDAQ:APTX): Insider trades (number of shares)
Period	Buy	Sel
Nov 2021	80000	0
Dec 2021	145000	0
Jan 2022	17700	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	13 Jan 2022	MILLER JOAN W. director director	Common Stock	17,700	$2.83	$50,091
Purchase	6 Dec 2021	RIEDEL NORBERT G director, officer..	Common Stock	100,000	$2.23	$223,000
Purchase	2 Dec 2021	KHANNA ASHISH officer: CFO AND ..	Common Stock	45,000	$2.26	$101,700
Purchase	12 Nov 2021	HOMBACH ROBERT J. director director	Common Stock	74,600	$2.4	$179,040
Purchase	11 Nov 2021	HOMBACH ROBERT J. director director	Common Stock	5,400	$2.4	$12,960
Option	17 May 2021	RIEDEL NORBERT G director, officer..	Restricted Stock Units	380,000	N/A	N/A
Option	17 May 2021	RIEDEL NORBERT G director, officer..	Common Stock	380,000	N/A	N/A
Option	17 May 2021	KHANNA ASHISH officer: CFO AND ..	Restricted Stock Units	130,000	N/A	N/A
Option	17 May 2021	KHANNA ASHISH officer: CFO AND ..	Common Stock	130,000	N/A	N/A
Option	17 May 2021	KIDD ANDREW officer: PRESIDENT & COO officer: PRESIDENT & COO	Restricted Stock Units	130,000	N/A	N/A

Status	Patent	Filling date	Issue date
Application	Application METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR Filling date: 30 Jul 2020 Issue date: 1 Sep 2022	30 Jul 2020	1 Sep 2022
Application	Application SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Filling date: 13 Aug 2021 Issue date: 14 Jul 2022	13 Aug 2021	14 Jul 2022
Grant	Grant Utility: Spiro-lactam NMDA receptor modulators and uses thereof Filling date: 1 Dec 2020 Issue date: 5 Jul 2022	1 Dec 2020	5 Jul 2022
Grant	Grant Utility: Spiro-lactam NMDA modulators and methods of using same Filling date: 1 Aug 2017 Issue date: 28 Jun 2022	1 Aug 2017	28 Jun 2022
Application	Application SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Filling date: 24 Jun 2021 Issue date: 19 May 2022	24 Jun 2021	19 May 2022
Grant	Grant Utility: Spiro-lactam NMDA receptor modulators and uses thereof Filling date: 1 Aug 2017 Issue date: 12 Apr 2022	1 Aug 2017	12 Apr 2022
Application	Application SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Filling date: 7 May 2021 Issue date: 31 Mar 2022	7 May 2021	31 Mar 2022
Application	Application SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Filling date: 17 Feb 2021 Issue date: 6 Jan 2022	17 Feb 2021	6 Jan 2022
Application	Application METHODS OF TREATING COGNITIVE IMPAIRMENT ASSOCIATED WITH NEURODEGENERATIVE DISEASE Filling date: 3 Dec 2020 Issue date: 21 Oct 2021	3 Dec 2020	21 Oct 2021
Application	Application SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Filling date: 1 Dec 2020 Issue date: 21 Oct 2021	1 Dec 2020	21 Oct 2021

Aptinyx
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 8 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 7 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 13 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 23 Mar 2022	Q4 2021 Earnings Call Transcript

APTX earnings call transcripts

Aptinyx
Executives

Insider	Age	Compensation
Dr. Norbert G. Riedel (1958) Executive Chairman	67	$826,780
Dr. Andrew D. Kidd B.M. B.Ch., M.D. (1977) Chief Executive Officer, Pres & Director	48	$594,370
Mr. Ashish Khanna (1976) Chief Financial Officer & Chief Bus. Officer	49	$580,190

Aptinyx
Latest News

Tuesday, 23 April 2024
08:00	Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO	businesswire.com
Thursday, 30 March 2023
16:05	Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives	businesswire.com
11:23	Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now	Zacks Investment Research
Tuesday, 21 March 2023
13:00	COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar	Zacks Investment Research
Tuesday, 28 February 2023
08:36	Why Is Aptinyx (APTX) Stock Down 64% Today?	InvestorPlace
Tuesday, 31 January 2023
07:47	Aptinyx to Present at the SVB Securities Global Biopharma Conference	Business Wire
Tuesday, 8 November 2022
21:46	Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 18 October 2022
07:45	Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022	Business Wire
Friday, 12 August 2022
12:48	Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal	Zacks Investment Research
Sunday, 7 August 2022
07:13	Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Friday, 15 July 2022
07:47	Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022	Business Wire
Wednesday, 18 May 2022
07:37	Aptinyx to Participate in H.C. Wainwright Global Investment Conference	Business Wire
Friday, 13 May 2022
12:50	Aptinyx, Inc. (APTX) CEO Andy Kidd on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Wednesday, 27 April 2022
07:47	Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022	Business Wire
Friday, 8 April 2022
12:47	Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal	Zacks Investment Research
Thursday, 7 April 2022
09:36	Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study	Benzinga
08:44	Aptinyx's stock falls 48% after drug fails in Phase 2b trial	Market Watch
Tuesday, 5 April 2022
06:59	7 Biotech Stocks to Buy With Key Catalysts for April	InvestorPlace
Wednesday, 23 March 2022
22:56	Aptinyx, Inc. (APTX) CEO Andy Kidd on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 21 March 2022
11:17	Has Aptinyx Inc. (APTX) Outpaced Other Medical Stocks This Year?	Zacks Investment Research
Wednesday, 9 March 2022
07:47	Aptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022	Business Wire
Friday, 4 March 2022
11:32	Is Aptinyx Inc. (APTX) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Tuesday, 8 February 2022
07:37	Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference	Business Wire
Monday, 13 December 2021
07:49	Aptinyx to Present at the 40th Annual J.P. Morgan Healthcare Conference	Business Wire
Friday, 10 December 2021
12:16	Are Options Traders Betting on a Big Move in Aptinyx (APTX) Stock?	Zacks Investment Research
Thursday, 9 December 2021
10:58	Aptinyx Stock (APTX): Why The Price Increased Today	Pulse2
Wednesday, 10 November 2021
01:43	Aptinyx, Inc. (APTX) CEO Norbert Riedel on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 25 October 2021
07:32	Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021	Business Wire
Thursday, 16 September 2021
06:37	Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures	Business Wire
Tuesday, 31 August 2021
07:57	Aptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment Conference	Business Wire

Ideas & Opinions

Seeking Alpha 21 Jul 2021

Aptinyx: CNS Drug Discoverer With Depressed Price

Frequently Asked Questions (FAQ)

What's the price of Aptinyx stock today?

One share of Aptinyx stock can currently be purchased for approximately $0.07.
When is Aptinyx's next earnings date?

Unfortunately, Aptinyx's (APTX) next earnings date is currently unknown.
Does Aptinyx pay dividends?

No, Aptinyx does not pay dividends.
What is Aptinyx's stock symbol?

Aptinyx Inc. is traded on the NASDAQ under the ticker symbol "APTX".
What is Aptinyx's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Aptinyx?

Shares of Aptinyx can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Aptinyx's key executives?
Aptinyx's management team includes the following people:
- Dr. Norbert G. Riedel Executive Chairman(age: 67, pay: $826,780)
- Dr. Andrew D. Kidd B.M. B.Ch., M.D. Chief Executive Officer, Pres & Director(age: 48, pay: $594,370)
- Mr. Ashish Khanna Chief Financial Officer & Chief Bus. Officer(age: 49, pay: $580,190)
How many employees does Aptinyx have?

As Jul 2024, Aptinyx employs 12 workers.
When Aptinyx went public?

Aptinyx Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
What is Aptinyx's official website?

The official website for Aptinyx is aptinyx.com.
Where are Aptinyx's headquarters?

Aptinyx is headquartered at 909 Davis Street, Evanston, IL.
How can i contact Aptinyx?

Aptinyx's mailing address is 909 Davis Street, Evanston, IL and company can be reached via phone at +84 78710377.

Aptinyx Inc.

aptinyx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

+84 78710377

909 Davis Street
Evanston, IL 60201

CIK: 0001674365
ISIN: US03836N1037
CUSIP: 03836N103